Houston, Texas - (NewMediaWire) - November 05, 2021 - In CHNC’s continuing quest to broaden its horizons while spreading education about medicinal cannabis, a new collaboration has been forged with well renowned Drs. Nada AL-Rubaiee.

CHNC is honored to work along with someone with such an impressive curriculum. With a Bachelor’s degree from Leiden University (The Netherlands) in Bio-pharmaceutical sciences, a Masters in Pharmacy from the same school and a degree as Doctor of Health Administration from Walden University (USA), her academic achievements can only be matched by her professional background. During her career, she has served as Managing Director of Nadafarm Healthcare, in addition, she is currently the owner and director of Lyndensteyn B.V. consultancy services in which she has developed great leadership and team management skills which contributed to her achievement as Ethnic Business Women of the Netherlands.

As CHNC’s new brand ambassador, Drs. Nada would act as an extension of Pharmacology University to pursue our goal of creating more international alliances with academic institutions. Undoubtedly, this is a growing industry worldwide and countries who have been traditionally against legalization, such as Lebanon, are now viewing it as an opportunity to aid their economy. According to Lebanon's minister of economy, medicinal cannabis exports could generate $1 billion in annual revenue for the country.

They are not alone in this prediction, as other countries in the region can expect a net income from growing this plant for medicinal purposes of over $11,000 US dollars per hectare per year.  Both Drs. Nada and CHNC agree that educational platforms play a key role in the industry as many of the stereotypes that have been created are a result of lack of information. Therefore, in this region it will be crucial to access education to make way for this blooming industry.

“We understand the complexities this industry entails, and the need to join forces with allies who have the same level of commitment with education as CHNC has. We could not have wished for a better representative than Drs. Nada. Her work and tenacity in the industry continues to inspire us to develop new educational options for the public,” says Jennifer Simbaña - CHNC’s Developer of International Markets.

This is another brick that paves the road to a financially successful 2022 while coming closer to our ultimate goal: being the international leader in education in the medical cannabis industry, in a market that promises to have global legal sales by 2026 of USD $90.4 billion (Business Wire).

To learn more visit: https://www.chnc-hdh.com/ 

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "projects," "intends," and similar phrases. Forward-looking statements involve risks and uncertainties that could cause actual results to differ from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of geopolitical conditions, competition, changes in technology and methods of marketing, and various other factors beyond the company's control.

For more information contact us at:
info@pharmacologyuniversity.com
817/528-2475 for English
214/733-0868 for Spanish